Dr. Jacobus J. Bosch, MD, PhD

CRC 1697 | Jacobus Bosch

Research Director Oncology
Centre for Human Drug Research
Leiden University, The Netherlands

Projects:

Project leader

Scientific career

1995 – 2004 Study of Medicine, Leiden University, Leiden, The Netherlands.

1996 Propaedeutic exam Medicine, Leiden University, Leiden, The Netherlands.

1999 – 2000 Chairperson of the Board of the Medical Interfacultary Congress Foundation (M.I.C.), Utrecht, The Netherlands.

2000 Doctoral exam Medicine, Leiden University, Leiden, The Netherlands.

2000 – 2002 Pre-Doctoral Research Fellowship in Ocular-Immunology, The Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, USA.

2004 Doctor of Medicine (M.D.), Leiden University, Leiden, The Netherlands.

2005 – 2008 Post-Doctoral Research Fellowship in Tumor-Immunology, University of Maryland, Baltimore, Maryland, USA

2007 – 2010 Member of the Associate Member Council, American Association for Cancer Research, Philadelphia, PA, USA.

2009 – Present Member of the Medical Advisory Board of the Ocular Melanoma Foundation, Richmond, VA, USA

2009 – 2022 Present Resident and Research Group Leader in Hematology and Medical Oncology, University Hospital Erlangen, Erlangen, Germany

2012 Doctor of Philosophy (Ph.D). in Medicine, specifically Tumor-Immunology, Leiden University, Leiden, The Netherlands.
B.I.G. registration number: 19062838701 (NL Medical Doctor database)

2015- Principal Investigator of Project 4 “Tumor-associated lymphangiogenesis and its inhibition as a novel therapeutic strategy in conjunctival melanomas” in the DFG Research Unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” at the Department of Medicine 5 Hematology and Medical Oncology at the University Hospital Erlangen

2018- Principal Investigator of Project P4 “The role of midkine in tumor-associated lymphangiogenesis and metastasis of ocular malignant melanoma” in the DFG Research Unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” at the Department of Medicine 5 Hematology and Medical Oncology at the University Hospital Erlangen

2022 – Research Director Oncology, Centra for Human Drug Research, Leiden University, The Netherlands

Prizes and honors

2009-2021 Member of the Medical Advisory Board, Ocular Melanoma Foundation, Richmond, VA, USA.

2020 SITC Team Science Award as Member of the SLP Stream Team, Society for Immunotherapy of Cancer (SITC), Washington DC, USA

2016 AMA Innovation Award for Magnetic Flowcytometry as Member of the BMBF-funded MRCyte-Consortium, Association for Sensors and Measurement (AMA), Sensor+Test Trade Fair, Nuremberg, Germany

2010 OMF Junior Investigator Award, Ocular Melanoma Foundation, annual meeting, Boston, MA, USA

2007-2010 Member of the Associate Member Council, American Association for Cancer Research, Philadelphia, PA, USA.

2007 AACR – Aflac Inc. Scholar-in-Training Award, American Association for Cancer Research, annual meeting, Los Angeles, CA, USA

2006 – 2007 Post-Doctoral Research Stipend, Fight for Sight Inc., New York, NY, USA

2002 ARVO Research Travel Award: Association of Research in Vision and Ophthalmology, annual meeting; Joseph M. and Eula G. Lawrence Retina Research Foundation, Houston, TX, USA

2000 – 2002 Research Scholarships of several scientific Foundations in the Netherlands

Selected publications

 

  1. Karg MM, John L, Refaian N, Buettner C, Rottmar T, Sommer J, Bock B, Resheq YJ, Ksander BR, Heindl LM, Mackensen A, Bosch JJ. Midkine Promotes Metastasis and Therapeutic Resistance via mTOR/RPS6 in Uveal Melanoma. Mol Cancer Res. 2022 Aug 5;20(8):1320-1336.
  2. Kremsner PG, Mann P, Kroidl A, Leroux-Roels I, Schindler C, Gabor JJ, Schunk M, Leroux-Roels G, Bosch JJ, Fendel R, Kreidenweiss A, Velavan TP, Fotin-Mleczek M, Mueller SO, Quintini G, Schönborn-Kellenberger O, Vahrenhorst D, Verstraeten T, Alves de Mesquita M, Walz L, Wolz OO, Oostvogels L; CV-NCOV-001 Study Group (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Epub ahead of print, Wien Klin Wochenschr. 2021 Aug 10:1–11.
  3. Menzner AK, Rottmar T, Voelkl S, Bosch JJ, Mougiakakos D, Mackensen A, Resheq YJ (2021). Hydrogen-Peroxide Synthesis and LDL-Uptake Controls Immunosuppressive Properties in Monocyte-Derived Dendritic Cells. Cancers, 13(3):461.
  4. Kittler JM, Sommer J, Fischer A, Britting S, Karg MM, Bock B, Atreya I, Heindl LM, Mackensen A, Bosch JJ (2019). Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines. Oncotarget. 10(19): 1812-1828.
  5. Resheq YJ, Menzner AK, Bosch JJ, Tickle J, Li KK, Wilhelm A, Hepburn E, Murihead G, Ward ST, Curbishley SM, Zimmermann HW, Bruns T, Gilbert DF, Tripal P, Mackensen A, Adams DH, Weston CJ (2017). Impaired Transmigration of Myeloid-Derived Suppressor Cells across Human Sinusoidal Endothelium Is Associated with Decreased Expression of CD13. Journal of immunology 199:1672-1681.
  6. Cursiefen C, Bock F, Clahsen T, Regenfuss B, Reis A, Steven P, Heindl LM, Bosch JJ, Hos D, Eming S, Grajewski R, Heiligenhaus A, Fauser S, Austin J, Langmann T. [New Therapeutic Approaches in Inflammatory Diseases of the Eye – Targeting Lymphangiogenesis and Cellular Immunity: Research Unit FOR 2240 Presents Itself]. Klin Monbl Augenheilkd. 2017 May;234(5):679-685.
  7. Refaian N, Schlereth SL, Koch KR, Notara M, Hos D, Mescher M, Iden S, Bosch JJ, Jager MJ, Cursiefen C, Heindl LM. Comparing the Hem- and Lymphangiogenic Profile of Conjunctival and Uveal Melanoma Cell Lines. Invest Ophthalmol Vis Sci. 2015;56(9):5691-7
  8. Gary R, Voelkl S, Palmisano R, Ullrich E, Bosch JJ, Mackensen A (2012) Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8+ T cells via trogocytosis. J Immunol. 188(2):744-52.
  9. Bosch JJ (2012) Immunotherapy of uveal melanoma. Dev Ophthalmol. 49:137-49.
  10. Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S (2007) MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res. 67:4499-506.